207 related articles for article (PubMed ID: 7001229)
21. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
Hildebrandt P
Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
[TBL] [Abstract][Full Text] [Related]
22. Control of insulin-dependent diabetes with portable miniaturized infusion systems.
Hepp KD; Renner R; Piwernetz K; Mehnert H
Diabetes Care; 1980; 3(2):309-13. PubMed ID: 6993145
[TBL] [Abstract][Full Text] [Related]
23. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin.
Freidenberg GR; White N; Cataland S; O'Dorisio TM; Sotos JF; Santiago JV
N Engl J Med; 1981 Aug; 305(7):363-8. PubMed ID: 7019707
[TBL] [Abstract][Full Text] [Related]
24. Insulin production rate in normal man as an estimate for calibration of continuous intravenous insulin infusion in insulin-dependent diabetic patients.
Waldhäusl WK; Bratusch-Marrain PR; Francesconi M; Nowotny P; Kiss A
Diabetes Care; 1982; 5(1):18-24. PubMed ID: 6754299
[TBL] [Abstract][Full Text] [Related]
25. Comparison between multi-injection and continuous subcutaneous insulin therapy in insulin-dependent diabetic inpatients.
Saibene V; Melandri M; Brembilla L; Spotti D; Pozza G
Acta Diabetol Lat; 1981; 18(1):45-50. PubMed ID: 7010856
[TBL] [Abstract][Full Text] [Related]
26. Hormonal and metabolic profiles in insulin-dependent diabetics under subcutaneous conventional and artificial endocrine pancreas (glucose continuous insulin infusion system Biostator) treatment.
Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Bellomo G; Antonella MA; Angeletti G; Massi-Benedetti M; Brunetti P
J Endocrinol Invest; 1983 Feb; 6(1):1-8. PubMed ID: 6341441
[No Abstract] [Full Text] [Related]
27. Long-term, ambulatory, subcutaneous insulin infusion versus multiple daily injections in brittle diabetic patients.
Barbosa J; Menth L; Eaton J; Sutherland D; Freier EF; Najarian J
Diabetes Care; 1981; 4(2):269-74. PubMed ID: 7011745
[TBL] [Abstract][Full Text] [Related]
28. Automatic learning algorithm for the MD-logic artificial pancreas system.
Miller S; Nimri R; Atlas E; Grunberg EA; Phillip M
Diabetes Technol Ther; 2011 Oct; 13(10):983-90. PubMed ID: 21774690
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal delivery of insulin by a portable microinfusion pump.
Eaton RP; Friedman NM; Spencerr WJ
Metabolism; 1980 Aug; 29(8):699-702. PubMed ID: 6995791
[TBL] [Abstract][Full Text] [Related]
30. A comparison of insulin regimens in insulin-dependent diabetes mellitus.
Skyler JS; Seigler DE; Reeves ML
Diabetes Care; 1982; 5 Suppl 1():11-8. PubMed ID: 6765118
[TBL] [Abstract][Full Text] [Related]
31. Closed-loop glycemic control with a wearable artificial endocrine pancreas. Variations in daily insulin requirements to glycemic response.
Shichiri M; Kawamori R; Hakui N; Yamasaki Y; Abe H
Diabetes; 1984 Dec; 33(12):1200-2. PubMed ID: 6389235
[TBL] [Abstract][Full Text] [Related]
32. Comparison of plasma glucose and plasma free insulin during CSII and intensified conventional insulin therapy.
Buysschaert M; Marchand E; Ketelslegers JM; Lambert AE
Diabetes Care; 1983; 6(1):1-5. PubMed ID: 6341010
[TBL] [Abstract][Full Text] [Related]
33. Open-loop device Microjet MC 2 improves unstable diabetes, lowers the daily insulin requirement and reduces the excursions of plasma free insulin levels: comparison with a traditional intensive treatment.
Micossi P; Raggi U; Dosio F; Scavini M; Bertin A; Pozza G
J Endocrinol Invest; 1983 Jun; 6(3):189-94. PubMed ID: 6352793
[No Abstract] [Full Text] [Related]
34. 24-hour blood glucose profiles in insulin-dependent diabetics treated with intravenous insulin infusion systems. A comparison between closed- and open-loop systems.
Deckert T; Bojsen J; Christiansen JS; Kølendorf K; Svendsen PA; Andersen AR
Acta Med Scand; 1980; 208(6):451-8. PubMed ID: 7008508
[TBL] [Abstract][Full Text] [Related]
35. Artificial endocrine pancreas and optimal blood glucose regulation in diabetic patients--from bedside-type to wearable-type.
Shichiri M; Kishikawa H; Sakakida M; Kajiwara K; Hashiguchi Y; Nishida K; Uemura T; Konno Y; Ichinose K
Diabetes Res Clin Pract; 1994 Oct; 24 Suppl():S251-9. PubMed ID: 7859615
[TBL] [Abstract][Full Text] [Related]
36. Considerations for the programming of an open-loop insulin infusion device from the biostator glucose controller.
Service FJ; Rizza RA; Westland RE; Hall LD; Nelson RL; Haymond MW; Clemens AH; Gerich JE
Diabetes Care; 1980; 3(2):278-84. PubMed ID: 6993141
[TBL] [Abstract][Full Text] [Related]
37. Use of long-term microdialysis subcutaneous glucose monitoring in the management of neonatal diabetes. A first case report.
Holzinger A; Bonfig W; Kusser B; Eggermann T; Müller H; Munch HG
Biol Neonate; 2006; 89(2):88-91. PubMed ID: 16166771
[TBL] [Abstract][Full Text] [Related]
38. Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects.
Santiago JV; Clemens AH; Clarke WL; Kipnis DM
Diabetes; 1979 Jan; 28(1):71-84. PubMed ID: 365656
[No Abstract] [Full Text] [Related]
39. Continuous subcutaneous insulin infusion:good blood glucose control for up to 4 days.
Pickup JC; Keen H; Parsons JA; Alberti KG
Diabetologia; 1979 Jun; 16(6):385-9. PubMed ID: 467848
[TBL] [Abstract][Full Text] [Related]
40. [Studies on stable control of blood sugar by continuous administration of insulin through isolated intestinal loop].
Saito H; Mashima Y; Tashiro T; Yamamori H; Horibe K; Nishizawa M; Okui K
Nihon Geka Gakkai Zasshi; 1992 Jan; 93(1):16-25. PubMed ID: 1372385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
